Patients With Advanced Lymphoid Malignancies in the Absence of an HLA Identical or Mismatch Donor Clinical Trial
Official title:
A Prospective Phase II Study to Evaluate Cord Blood Transplantation in Patients With Advanced Lymphoid Malignancies.
Indication: Patients with advanced lymphoid malignancies in the absence of an HLA identical
or mismatch donor.
Objectives: Overall survival at one year. Efficacy >60%, rejection rate <20%. Inclusion
criteria: Age: 18-65 years old, no sibling or unrelated donor identified, low grade
non-hodgkin lymphoma in third line (who already received at least one autologous
transplantation); hodgkin lymphoma in early relapse (<1 year), who received at least one
autologous transplantation and sensible to chemotherapy and CLL with 17p deletion or in
relapse less than 2 year after a fludarabine nbased regimen or in relapse after one
autologous transplantation.
Stem cell source: Two cord blood units containing both together more than 3x107 frozen
nucleated cells/Kg with no more than 2 out of 6 HLA mismatches between them and with the
patients.
n/a